Sarepta Therapeutics (SRPT) stock, explained like you're 5

Is Sarepta Therapeutics a small, medium or large cap company?

No. Sarepta Therapeutics is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 1.9 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Sarepta Therapeutics makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves SRPT stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• SRPT Stock Climbs After Sarepta Seeks Permanent FDA Nod For Two Duchenne Therapies (Stocktwits)
• DM1 RNA Knockdown Data Might Change The Case For Investing In Sarepta Therapeutics Stock (Simply Wall Street)
• Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments (Sarepta Therapeutics)
• Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP 1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting (Business Wire)
• Morgan Stanley Views Sarepta CEO Transition As A ‘Positive’ So, Why Is It Cautious On SRPT Stock In The Near Term? (Stocktwits)

Key terms to know before you follow SRPT

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility